Optimistic Outlook for Syros Pharmaceuticals with Promising Clinical Trials and Regulatory Advancements

2d ago, source:

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Syros Pharmaceuticals (SYRS – Research Report), ...

SYRS Syros Pharmaceuticals, Inc.

1mon ago, source: Seeking Alpha

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene ...

Syros Pharmaceuticals Inc SYRS

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Buy Rating Affirmed for Syros Pharmaceuticals Amidst Clinical Advancements and Market Readiness

3d ago, source:

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) and keeping the price ...

Syros Pharmaceuticals Inc.

18d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Syros Pharmaceuticals Inc SYRS

25d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...